DSG2 and neoplasm: In addition to targeting DCs via CD80/CD86, Ad3-based oncolytic adenoviruses are currently being developed for clinical use to directly target the tumor microenvironment, through binding of Ad3 to tumor-expressed desmoglein-2, a receptor used by various type B adenoviruses and expressed on several cancer types [29,41,73,74,75].